Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18021885 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL4408001 | 0.76 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL4407475 | 0.76 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL4412009 | 0.74 | PKM (0.34) | CNR1CNR2 | |
| SCHEMBL4413432 | 0.74 | CNR1 (0.32) | CNR1CNR2 | |
| SCHEMBL4408285 | 0.72 | SLC6A2 (0.31) | CNR1CNR2 | |
| SCHEMBL4414548 | 0.72 | ALDH1A1 (0.32) | CNR1CNR2 | |
| SCHEMBL4405551 | 0.72 | CNR1 (0.31) | CNR1CNR2 | |
| SCHEMBL4407947 | 0.71 | PKM (0.33) | CNR1CNR2 | |
| SCHEMBL4404340 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230339844-A1 | A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339844-A1 | A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2023-10-26 | — | — | US | disclosed |
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | PI INDUSTRIES LTD. (IN) | 2023-08-08 | — | — | US | disclosed |
| US-20220144814-A1 | A PROCESS FOR PREPARING ANTHRANILIC DIAMIDES AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2022-05-12 | — | — | US | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2021-11-18 | — | — | US | disclosed |
| EP-1859782-B1 | Composition for coloring and/or lightening human hair comprising tetrazoles | HENKEL AG & CO KGAA (DE) | 2009-12-30 | — | — | EP | disclosed |
| EP-1859782-A1 | Composition for coloring and/or lightening human hair comprising tetrazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | DAO, DDC, QDPR | CNR1 3202/4885CNR2 2351/4885 |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | CNR1 4000/4885CNR2 4603/4885 |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | LRRK2, PARK7, BRCA1 | CNR1 2094/4885CNR2 2304/4885 |
| US-20220144814-A1 | A PROCESS FOR PREPARING ANTHRANILIC DIAMIDES AND INTERMEDIATES THEREOF | F12, IDH3B, CA7 | CNR1 755/4885CNR2 660/4885 |
| US-20230339844-A1 | A PROCESS FOR THE SYNTHESIS OF ANTHRANILIC ACID/AMIDE COMPOUNDS AND INTERMEDIATES THEREOF | ASS1, ACMSD, ADCY10 | CNR1 1450/4885CNR2 1556/4885 |
| US-20210355117-A1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, BRCA1 | CNR1 2175/4885CNR2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.